On Thursday, November 8 we had the honor of traveling to Montreal, Canada to attend a town hall meeting and inspire Novartis Canada employees.

There, we were joined by Children’s Hospital of Philadelphia’s (CHOP) Dr. Stephan Grupp and the Lahti family, whose son Cameron received CAR-T cell therapy at CHOP in July 2016.

In September of this year, Canada joined the European Union and United States in granting Novartis CAR-T cell therapy Kymriah™ (tisagenlecleucel/ CTL019) regulatory approval for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and adult patients with relapsed/refractory non-Hodgkin’s lymphoma (DLBCL).

This treatment is the same that Emily and Cameron were fortunate to receive in the CTL019 clinical trials at CHOP. We continue to be very thankful that many more children and adults around the world will now have the opportunity to receive this therapy as well.

We enjoyed the trip and are very thankful for the opportunity to inspire Novartis Canada with our story! It is our hope that our travels continue to spread awareness and lead more people to find hope in new and innovative cancer immunotherapy treatments.